MediciNova Inc (MNOV) stock
Close on Nov 12, 2026Market cap $68.91MP/E –Yield –
MediciNova Inc reported revenue of $935.72K for the twelve months to Sep 30, 2026. Free cash flow was -$9.80M. At the latest close the market valued the company at $68.91M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $68.91M
- P/E ratio
- –
- Price to sales
- 73.64
- Price to book
- 1.68
- Dividend yield
- –
- Free cash flow yield
- -14.23%
Fundamentals
- Revenue
- $935.72K
- Net income
- -$10.55M
- EPS, diluted
- -$0.22
- Free cash flow
- -$9.80M
- Book value per share
- $0.83
- Diluted shares
- 49M
Trading
- Previous close
- $1.41
- Open
- $1.40
- Day's range
- $1.40 – $1.42
- Volume
- 12,130
- Average volume (20 days)
- 52,260
- Beta (5 years)
- 0.39
- 52-week range
- $1.22 – $3.90
- RSI (14 days)
- 40.0
- Volatility (1 year)
- 73.8%
- Relative volume
- 0.05×
- WACC
- 7.5%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | MNOV | S&P 500 | Difference | MNOV per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -9.1% | -2.7% | −6.4 pts | ||
| 3 months | +5.3% | -1.7% | +7.0 pts | ||
| Year to date | +6.9% | +11.9% | −5.0 pts | ||
| 1 year | -10.8% | +12.0% | −22.8 pts | ||
| 3 years | -21.3% | +78.2% | −99.5 pts | -7.7% | +21.2% |
| 5 years | -60.6% | +73.2% | −133.8 pts | -17.0% | +11.6% |
| 10 years | -80.8% | +309.6% | −390.4 pts | -15.2% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases MediciNova filed with the SEC as exhibits to Form 8-K or 6-K
About MediciNova
Pharmaceutical Preparations
MediciNova, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious medical conditions with unmet needs, primarily targeting the United States commercial market. Its research and development efforts center on two principal product candidates: MN-166 (ibudilast) and MN-001 (tipelukast). MN-166 is an oral anti-inflammatory and neuroprotective agent being investigated for neurological and respiratory indications, including progressive multiple sclerosis, amyotrophic lateral sclerosis, degenerative cervical myelopathy, glioblastoma, and the prevention of acute respiratory distress syndrome. MN-001 is evaluated for fibrotic and metabolic conditions, including nonalcoholic fatty liver disease and hypertriglyceridemia. The company engages with trial participants and works alongside research institutions, government entities, and corporate partners.
Company profile, executives and historyMediciNova stock: common questions
What is MediciNova's stock price?
MNOV closed at $1.40 on Nov 12, 2026, down 0.71% on the day. Over the past 52 weeks it traded between $1.22 and $3.90.
What is MediciNova's market cap?
MediciNova was worth $68.91M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is MNOV's P/E ratio?
MediciNova lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.22), so it has no meaningful P/E ratio.
How much revenue does MediciNova make?
MediciNova reported revenue of $935.72K for the twelve months to Sep 30, 2026.
Does MediciNova pay a dividend?
No. MediciNova has not paid a cash dividend over the last twelve months.
How has MNOV stock performed over the past year?
Including dividends, MNOV returned -10.8% over the past year, against +12.0% for the S&P 500.
How many MNOV shares are sold short?
0M shares were sold short at the latest FINRA report, 0.66% of the float, or 5.4 days of average trading volume.
Who are MediciNova's competitors?
Companies most similar to MediciNova by business, industry and size include SPRB, VCNX, IBIO, YARW, LGVN.
See a number that looks wrong?